Centers of Psychiatric Excellence (COPE) to Present New Research on Ketamine at The American Psychiatric Association's Annual Meeting in New York City on May 7

Tuesday, May 1, 2018 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, May 1, 2018 /PRNewswire/ -- The Centers of Psychiatric Excellence (COPE) is pleased to present new research on

the drug ketamine at The American Psychiatric Association's (APA) Annual Meeting in New York, NY, on Monday, May 7. The presentations will take place from 1:00 – 4:00
p.m.
in room 1A14 on the first floor of The Javits Center.  

COPE's session is called "Advances in Ketamine Research and Clinical Practice: Need for Evidence-Based Practice Guidelines" and will include the following presentations:

Chair: Steven Szabo, M.D. (Duke University)  

  • Preclinical and Translational Neuroscience: A Brief History of Ketamine, presented by Gerard Sanacora, M.D., Ph.D. (Yale University)
  • Updates on Subanesthetic Doses of Ketamine for Mood Spectrum Disorders, presented by Sanjay J. Mathew, M.D. (Baylor University)
  • Updates on Subanesthetic Doses of Ketamine for Anxiety Spectrum Disorders, presented by James W. Murrough, M.D.(Mt Sinai,NY)
  • Updates on Subanesthetic Doses of Ketamine for Management of Chronic Pain, presented by Ashwin A Patkar, M.D. ( Duke University)
  • Development of Centers of Psychiatric Excellence and a Registry to Optimize Ketamine Administrations, presented by Prakash S. Masand, M.D. (Duke–National University of Singapore)
  • Panel Discussion, led by Carlos A. Zarate, M.D. (National Institute of Mental Health)

"Studies show overwhelming evidence to support the efficacy of ketamine in the most difficult to treat cases of major depression, anxiety, bipolar depression, chronic pain and opioid addiction," said Dr. Prakash Masand, CEO of Centers of Psychiatric Excellence (COPE) and Adjunct Professor, Duke-NUS. "We are excited to share this important information at this year's APA annual meeting."

For more information about COPE's session on Ketamine, visit https://www.copepsychiatry.com/advances-in-ketamine-research-and-clinical-practice-need-for-evidence-based-practice-guidelines/

About COPE COPE (Centers of Psychiatric Excellence) is a management services organization that offers administrative and advisory support to independently operated psychiatric treatment clinics. COPE is proud to partner with highly specialized clinics around the country that service the most difficult to treat cases of depression, anxiety (specifically PTSD), and chronic pain. 

COPE was founded by three internationally renowned psychiatrists at Duke University Medical Center: Prakash Masand, MD; Ashwin Patkar, MD; and Steven Szabo, MD. In their more than 60 years of clinical and academic experience, they saw a clear, unmet need to provide support and services to facilities that offer evidence-based, innovative treatment.You can visit https://www.copepsychiatry.com/

Media Contact Prakash Masand MD 919-619-5101 prakashmasand@copepsychiatry.com

Cision View original content:http://www.prnewswire.com/news-releases/centers-of-psychiatric-excellence-cope-to-present-new-research-on-ketamine-at-the-american-psychiatric-associations-annual-meeting-in-new-york-city-on-may-7-300640257.html

SOURCE Centers of Psychiatric Excellence



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store